Major Changes Coming with IVDR

In Vitro Diagnostic Regulation (IVDR) Changes 2021

Listen to this IVDR highlight from RCA Radio where Seyed Khorashahi breaks down the EU’s move from list-based IVD device classifications to a rule-based IVD medical device classification, resulting in four new device classes.
 

 

Listen to the entire episode where we go over all of the important things happening in the Medical Device industry here.


Need help with your transition to the IVDR? Contact Us Now →


Device Classification Changes

  • List-based Classification to a Rule-Based 
    • Class A (lowest risk) to class D (highest risk), where class B, C, and D would require Notified Body (NB) involvement.
  • MDGC 202- 16 Guidance on Classification for in vitro diagnostic Medical Devices under Regulation (EU) 2017/746.

Lifecycle Approach

  • Establishment and Demonstration of effective Quality Management Systems (QMS).
  • More stringent requirements for clinical evidence that demonstrates conformity.
  • Post-Market Performance monitoring and reporting requirements.
  • Introduction of Unique Device Identifiers (UDIs) for improved traceability.

Supply Chain Oversight

  • Regulations covering the entire supply chain.
    • Economic Operators
      • Importers
      • Distributors
      • Authorized Representatives
  • Notified Bodies have discretionary authority to audit suppliers and subcontractors

About Seyed Khorashahi 

Seyed Khorashahi has more than 25 years’ experience leading R&D teams in all aspects of developing safety-critical medical devices. He has held leadership positions at Covidien (Medtronic), Baxter, and Beckman Coulter, Inc., and has an extensive background in medical device product development, quality systems, regulatory affairs, and mergers and acquisitions. Other core competencies include engineering and business strategy.

Seyed has significant domain expertise not only in FDA and EU standards but also in software systems and hardware development for medical devices. A passionate innovator, he is a skilled collaborator as well, with recognized leadership capabilities and a relentless drive to overcome technical and business challenges. He is an influencer, consensus-builder, and a leader with success in establishing and managing relationships with external partners, executives, and internal multi-functional teams.

 

News

Vice News Interview: Coronavirus Is Revealing Gaping Holes in America’s Drug Supply Chain...
Read More

News

Vice News Interview: Coronavirus Is Revealing Gaping Holes in America’s Drug Supply Chain...
Read More

News

Vice News Interview: Coronavirus Is Revealing Gaping Holes in America’s Drug Supply Chain...
Read More
Regulatory Compliance Associates® Inc. Welcomes Steven Lynn as Executive Vice President of Pharmaceuticals...
Read More
2018 Compounding Policy Priorities Plan...
Read More

Our website uses cookies to give you the best possible experience.

By continuing to use this site, you agree to the use of cookies.
Continue